PARI and BOC collaborate to develop innovative drug delivery systems
PARI, a worldwide leader in aerosol delivery, and BOC, a global provider of medical gases, have signed an agreement to study the effects of gas-enabled drug delivery systems using Heliox. Heliox, the common name for mixtures of helium and oxygen, is three times lighter than air, which makes it easier for patients with compromised lung function to breathe.
PARI, a worldwide leader in aerosol delivery, and BOC, a global provider of medical gases, have signed an agreement to study the effects of gas-enabled drug delivery systems using Heliox. Heliox, the common name for mixtures of helium and oxygen, is three times lighter than air, which makes it easier for patients with compromised lung function to breathe.
It is hoped that the creation of an innovative Heliox delivery device with a customised nebuliser will help critically ill patients by delivering oxygen and aerosol to the lungs with less effort than breathing air. The goal is to improve the delivery range of aerosol therapies used to treat exacerbations of conditions such as asthma, COPD and bronchiolitis.
"Our collaboration with BOC marks an important step towards a commercially available aerosol delivery system that optimises results using gases other than air or enriched oxygen," said Werner Gutmann, president of PARI Respiratory Equipment, the North American arm of PARI GmbH. "We are certain that PARI's history in developing aerosol delivery systems can improve patient outcomes when using Heliox as well."
"We're delighted that PARI shares our vision of novel, easy-to-use drug delivery systems that will enable doctors to safely and reliably provide potentially lifesaving therapies," added Brad Walker, managing director of BOC's medical division.